Gilead Sciences : GILD

All Gilead Sciences Articles

734 Articles

Douglas A. McIntyre | Sep 2, 2009 at 8:21 AM EDT

Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)

These are the top ten analyst research initiations, upgrades, and downgrades we have seen from top Wall Street firms early…

Douglas A. McIntyre | Jul 22, 2009 at 7:53 AM EDT

Top Day Trader Alerts (CIT, ONXX, HGSI, WINN, OFG, AAPL, AMD, YHOO, SBUX, AMLN, GILD)

The following are some of the top stocks to watch for active trading today based on pre-market and after-hours volume…

Douglas A. McIntyre | Jul 22, 2009 at 4:01 AM EDT

The Next Blockbuster Drugs: A $170 Billion Opportunity

Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line…

Douglas A. McIntyre | Jul 13, 2009 at 10:25 AM EDT

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed…

Douglas A. McIntyre | Jun 25, 2009 at 11:31 AM EDT

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Novartis AG (NYSE: NVS) shares are at session highs and well of the lows of the day in the early…

Douglas A. McIntyre | Apr 27, 2009 at 6:40 AM EDT

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

Monday is looking like a SWINE FLU speculative flu stock stock bonanza, and we want to caution about some of…

Douglas A. McIntyre | Mar 12, 2009 at 8:10 AM EDT

Gilead Wins CV Therapeutics Bid; Higher Bid Coming? (GILD, CVTX)

Gilead Sciences, Inc. (Nasdaq: GILD) has agreed to buy CV Therapeutics, Inc. (Nasdaq: CVTX) for $20.00 per share in cash.

Douglas A. McIntyre | Feb 5, 2009 at 5:57 PM EST

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Biogen Idec Inc. (NASDAQ: BIIB) is set to report earnings on Friday morning. What many investors probably want to know…

Douglas A. McIntyre | Jan 5, 2009 at 7:15 AM EST

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT…

Douglas A. McIntyre | Dec 23, 2008 at 7:38 AM EST

Top Analyst Upgrades & Downgrades (ACM, AXYS, CTAS, CVD, GILD, PPDI, VISN, EPG, VTIV)

It is getting pretty thin in major analyst coverage as firms are encouraged to go easy on major year-end calls…

Douglas A. McIntyre | Dec 15, 2008 at 7:52 AM EST

Top Pre-Market Analyst Upgrades (MO, BBY, CFL, CEPH, GILD, LMT, TNDM, NOC, TLAB, MTN)

These are the top pre-market upgrades and positive analyst calls we have seen from Wall Street this Monday morning: Altria…

Douglas A. McIntyre | Dec 10, 2008 at 11:04 AM EST

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally…

Douglas A. McIntyre | Oct 16, 2008 at 3:23 PM EDT

Gilead Boosted Partly By Currencies (GILD)

Gilead Sciences Inc. (NASDAQ: GILD) has just issued its third quarter earnings at $0.52 net EPS and $0.55 non-GAAP EPS…

Douglas A. McIntyre | Sep 17, 2008 at 8:03 AM EDT

Day Trader Alert: Gilead Sciences (GILD)

Gilead Sciences Inc. (NASDAQ: GILD) is trading down this morning. Goldman Sachs maintained its buy rating on the stock, but…

Douglas A. McIntyre | Sep 12, 2008 at 6:28 AM EDT

Top Pre-Market Analyst Upgrades (DBD, FFIV, FSLR, GILD, GHL, WM)

There are surprisingly few analyst calls today, but these are some of the top positive calls and upgrades with more…

1 … 46 47 48 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)

Top Day Trader Alerts (CIT, ONXX, HGSI, WINN, OFG, AAPL, AMD, YHOO, SBUX, AMLN, GILD)

The Next Blockbuster Drugs: A $170 Billion Opportunity

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

Gilead Wins CV Therapeutics Bid; Higher Bid Coming? (GILD, CVTX)

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Top Analyst Upgrades & Downgrades (ACM, AXYS, CTAS, CVD, GILD, PPDI, VISN, EPG, VTIV)

Top Pre-Market Analyst Upgrades (MO, BBY, CFL, CEPH, GILD, LMT, TNDM, NOC, TLAB, MTN)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Gilead Boosted Partly By Currencies (GILD)

Day Trader Alert: Gilead Sciences (GILD)

Top Pre-Market Analyst Upgrades (DBD, FFIV, FSLR, GILD, GHL, WM)

The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

Forget Micron. The SK Hynix IPO is What Should Have Investors Pumped

The Hardest Retirement Money Decisions Pile Up Just as the Mind Slows. A 68-Year-Old Is Locking In Her Social Security and Tax Moves While She’s Sharp.

The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

The Hardest Retirement Money Decisions Pile Up Just as the Mind Slows. A 68-Year-Old Is Locking In Her Social Security and Tax Moves While She's Sharp.

The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

Forget Micron. The SK Hynix IPO is What Should Have Investors Pumped

Gilead Sciences : GILD

All Gilead Sciences Articles

Top Analyst Upgrades and Downgrades (BIIB, FRX, GENZ, GILD, HOLX, LVS, MOS, NVAX, RIG, TXT)

Top Day Trader Alerts (CIT, ONXX, HGSI, WINN, OFG, AAPL, AMD, YHOO, SBUX, AMLN, GILD)

The Next Blockbuster Drugs: A $170 Billion Opportunity

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Generic Biotech Drug Approval in Japan, Implications in U.S. and Abroad (NVS, PFE, AZN, AMGN, GENZ, GILD, CELG)

Swine Flu Lessons from SARS, Mad Cow & Bird Flu of Past (GILD, BCRX, NVAX, GNBT, VICL, AVII, CRXL, RHHBY, GSK, SFD, EWW, MXF)

Gilead Wins CV Therapeutics Bid; Higher Bid Coming? (GILD, CVTX)

Can Biogen Idec Earnings Generate A Buyout? (BIIB, AMGN, GILD, GENZ, CELG, MRK, SNY, GSK)

Is Pfizer About To Be On Acquisition Path? (PFE, AMGN, WYE, GILD, BMY, LLY, SGP, CELG, GENZ, BIIB)

Top Analyst Upgrades & Downgrades (ACM, AXYS, CTAS, CVD, GILD, PPDI, VISN, EPG, VTIV)

Top Pre-Market Analyst Upgrades (MO, BBY, CFL, CEPH, GILD, LMT, TNDM, NOC, TLAB, MTN)

Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)

Gilead Boosted Partly By Currencies (GILD)

Day Trader Alert: Gilead Sciences (GILD)

Top Pre-Market Analyst Upgrades (DBD, FFIV, FSLR, GILD, GHL, WM)

The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

Forget Micron. The SK Hynix IPO is What Should Have Investors Pumped

The Hardest Retirement Money Decisions Pile Up Just as the Mind Slows. A 68-Year-Old Is Locking In Her Social Security and Tax Moves While She’s Sharp.

Featured Reads

The 20-Year Dividend Strategy Built For Investors Who Don’t Need Income Yet

The Hardest Retirement Money Decisions Pile Up Just as the Mind Slows. A 68-Year-Old Is Locking In Her Social Security and Tax Moves While She's Sharp.